Abstract
Macrocyclic lactones (MLs) revolutionized parasite control in horses and other animals. They are unique in that they are effective against arthropods and nematodes. The first of the widely used avermectins was ivermectin. In 1983, it was marketed for use in horses as an injectable formulation but was withdrawn in 1984 after about a year and half on the market because of adverse problems. It was replaced by a paste formulation and an oral/stomach tube liquid formulation. Ivermectin is highly active on bots, ascarids, large and small strongyles, pinworms, strongyloides, stomach worms, and some other internal parasite species. Another ML, moxidectin, became available in 1997 as a gel formulation for oral administration. The parasiticidal activity of this compound is similar to ivermectin except efficacy is less on the common bot (Gastrophilus intestinalis) but high on encysted small strongyles. Recently however lower than initial activity on ascarids and small strongyles has been found for both ivermectin and moxidectin.
Keywords: Bots, ectoparasites, efficacy, equids, internal parasites, ivermectin, macrocyclic lactones, moxidectin, nematodes, toxicosis, treatment
Current Pharmaceutical Biotechnology
Title:Macrocyclic Lactones for Parasite Control in Equids
Volume: 13 Issue: 6
Author(s): E. T. Lyons and S. C. Tolliver
Affiliation:
Keywords: Bots, ectoparasites, efficacy, equids, internal parasites, ivermectin, macrocyclic lactones, moxidectin, nematodes, toxicosis, treatment
Abstract: Macrocyclic lactones (MLs) revolutionized parasite control in horses and other animals. They are unique in that they are effective against arthropods and nematodes. The first of the widely used avermectins was ivermectin. In 1983, it was marketed for use in horses as an injectable formulation but was withdrawn in 1984 after about a year and half on the market because of adverse problems. It was replaced by a paste formulation and an oral/stomach tube liquid formulation. Ivermectin is highly active on bots, ascarids, large and small strongyles, pinworms, strongyloides, stomach worms, and some other internal parasite species. Another ML, moxidectin, became available in 1997 as a gel formulation for oral administration. The parasiticidal activity of this compound is similar to ivermectin except efficacy is less on the common bot (Gastrophilus intestinalis) but high on encysted small strongyles. Recently however lower than initial activity on ascarids and small strongyles has been found for both ivermectin and moxidectin.
Export Options
About this article
Cite this article as:
T. Lyons E. and C. Tolliver S., Macrocyclic Lactones for Parasite Control in Equids, Current Pharmaceutical Biotechnology 2012; 13 (6) . https://dx.doi.org/10.2174/138920112800399310
DOI https://dx.doi.org/10.2174/138920112800399310 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Alcohol Related Changes in Regulation of NMDA Receptor Functions
Current Neuropharmacology New Pharmacological Approaches to the Prevention of Myocardial Ischemia- Reperfusion Injury
Current Drug Targets Unraveling the Action Mechanism of Buyang Huanwu Tang (BYHWT) for Cerebral Ischemia by Systematic Pharmacological Methodology
Combinatorial Chemistry & High Throughput Screening The Pulse of Drug Development for Alzheimers Disease
Reviews on Recent Clinical Trials Molecular and Clinical Aspects of the Target Therapy with the Calcimimetic Cinacalcet in the Treatment of Parathyroid Tumors
Current Cancer Drug Targets Insights Into the Molecular Aspects of Neuroprotective Bacoside A and Bacopaside I
Current Neuropharmacology The Role of Pro-Inflammatory Molecules and Pharmacological Agents in Acute Pancreatitis and Sepsis
Inflammation & Allergy - Drug Targets (Discontinued) The Role of Oxazolidine Derivatives in the Treatment of Infectious and Chronic Diseases
Current Bioactive Compounds Current Biological Therapies for Inflammatory Bowel Disease
Current Pharmaceutical Design Pneumonia in the Burn Patient
Current Respiratory Medicine Reviews Dietary Approaches and Alternative Therapies for Rheumatoid Arthritis
Current Nutrition & Food Science Efficacy and Safety Profile of Aliskiren: Practical Implications for Clinicians
Current Drug Safety Patients’ Induced Pluripotent Stem Cells to Model Drug Induced Adverse Events: A Role in Predicting Thiopurine Induced Pancreatitis?
Current Drug Metabolism Matrix Metalloproteinase Inhibition in Atherosclerosis and Stroke
Current Molecular Medicine The Central Vasopressinergic System: Examining the Opportunities for Psychiatric Drug Development
Current Pharmaceutical Design Fibromyalgia: The Prototypical Central Sensitivity Syndrome
Current Rheumatology Reviews Evolving Insights into the Pathophysiology of Diabetic Neuropathy: Implications of Malfunctioning Glia and Discovery of Novel Therapeutic Targets
Current Pharmaceutical Design Oxidative Stress: Apoptosis in Neuronal Injury
Current Alzheimer Research Telomeres, Senescence and Longevity: The Role of Oxidative Stress and Antioxidants
Current Pharmacogenomics The Therapeutic Role of Taurine in Ischaemia-Reperfusion Injury
Current Pharmaceutical Design